Topic: Dimebon

Pfizer, Medivation End Drug Deal

Sci-Tech Today - 21 days ago
In a major setback for patients and doctors, drugmakers Pfizer Inc. and Medivation Inc. have halted development of a potential Alzheimer's disease...

A.M. Vitals: Pfizer, Medivation End Dimebon Development

Wall Street Journal Health Blog - 23 days ago
Ending Dimebon Development: Pfizer and Medivation are ceasing development of Dimebon, an experimental Alzheimer's treatment, the WSJ reports. It...

Health Highlights: Jan. 18, 2012

Drugs.com - 30 days ago
Tweet . Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:. . Development of Experimental...

3 Biotech Stocks You Should Sell Before 2012

SeekingAlpha - 72 days ago
When the calendar flips from December to January, many people like to start the year with a clean slate.. . They swear off junk food and promise to...

Hapoalim Reiterates Hold On Medivation (MDVN)

Benzinga.com - 312 days ago
Posted on 04/11/11 at 10:09am by Roger Nachman . Hapoalim Securities is reiterating its Hold rating on Medivation (NASDAQ: MDVN ).. . In a note to...

Medivation: The Most Promising Upcoming Prostate Cancer Treatment

SeekingAlpha - 325 days ago
Prostate cancer is the most common form of cancer among men, and two companies - Medivation (MDVN) and Johnson & Johnson (JNJ) - are leading the...

Medivation CEO Discusses Q3 2010 Results - Earnings Call Transcript

SeekingAlpha - 469 days ago
Medivation, Inc. (MDVN) Q3 2010 Earnings Call Transcript November 05, 2010 4:30 pm ET. Thank you for joining Medivation's Third Quarter 2010 Financial Results Conference Call. Thank you and welcome to Medivation's third quarter 2010 financial results conference call ...

Dimebolin

Mahalo - 470 days ago
Dimebolin hydrochloride (brand name Dimebon ) is an antihistamine drug which has been used clinically in Russia since 1983. //clinicaltrials.gov/ct2/show/NCT00838110 "A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's ...

Medivation Narrows Loss

SeekingAlpha - 555 days ago
Medivation Inc. (MDVN) reported a loss of 21 cents per share in the second quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 29 cents. The upfront payments are being recognized ...

Medivation, Inc. Q2 2010 Earnings Call Transcript

SeekingAlpha - 557 days ago
Medivation, Inc. (MDVN) Q2 2010 Earnings Call Transcript August 09, 2010 4:30 am ET. On the call today from Medivation, are Dr. David Hung, President and CEO, Patrick Machado, Chief Business and Financial Officer, Dr. Lynn Seely, Chief Medical Officer and ...